Cargando…

Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan

There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuru, Mitsunobu, Yanamoto, Souichi, Yamada, Shin-ichi, Nakashiro, Kohichi, Harazono, Yosuke, Kohgo, Tomoyuki, Nakamura, Moriyoshi, Nomura, Takeshi, Kasamatsu, Atsushi, Tanaka, Susumu, Kirita, Tadaaki, Kioi, Mitomu, Ogawa, Masaru, Sasaki, Masashi, Ota, Yoshihide, Umeda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002461/
https://www.ncbi.nlm.nih.gov/pubmed/36901553
http://dx.doi.org/10.3390/ijerph20054545
_version_ 1784904395568185344
author Otsuru, Mitsunobu
Yanamoto, Souichi
Yamada, Shin-ichi
Nakashiro, Kohichi
Harazono, Yosuke
Kohgo, Tomoyuki
Nakamura, Moriyoshi
Nomura, Takeshi
Kasamatsu, Atsushi
Tanaka, Susumu
Kirita, Tadaaki
Kioi, Mitomu
Ogawa, Masaru
Sasaki, Masashi
Ota, Yoshihide
Umeda, Masahiro
author_facet Otsuru, Mitsunobu
Yanamoto, Souichi
Yamada, Shin-ichi
Nakashiro, Kohichi
Harazono, Yosuke
Kohgo, Tomoyuki
Nakamura, Moriyoshi
Nomura, Takeshi
Kasamatsu, Atsushi
Tanaka, Susumu
Kirita, Tadaaki
Kioi, Mitomu
Ogawa, Masaru
Sasaki, Masashi
Ota, Yoshihide
Umeda, Masahiro
author_sort Otsuru, Mitsunobu
collection PubMed
description There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin.
format Online
Article
Text
id pubmed-10002461
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100024612023-03-11 Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan Otsuru, Mitsunobu Yanamoto, Souichi Yamada, Shin-ichi Nakashiro, Kohichi Harazono, Yosuke Kohgo, Tomoyuki Nakamura, Moriyoshi Nomura, Takeshi Kasamatsu, Atsushi Tanaka, Susumu Kirita, Tadaaki Kioi, Mitomu Ogawa, Masaru Sasaki, Masashi Ota, Yoshihide Umeda, Masahiro Int J Environ Res Public Health Article There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin. MDPI 2023-03-03 /pmc/articles/PMC10002461/ /pubmed/36901553 http://dx.doi.org/10.3390/ijerph20054545 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Otsuru, Mitsunobu
Yanamoto, Souichi
Yamada, Shin-ichi
Nakashiro, Kohichi
Harazono, Yosuke
Kohgo, Tomoyuki
Nakamura, Moriyoshi
Nomura, Takeshi
Kasamatsu, Atsushi
Tanaka, Susumu
Kirita, Tadaaki
Kioi, Mitomu
Ogawa, Masaru
Sasaki, Masashi
Ota, Yoshihide
Umeda, Masahiro
Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title_full Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title_fullStr Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title_full_unstemmed Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title_short Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
title_sort radiotherapy plus cetuximab for squamous cell carcinoma of the oral cavity: a multicenter retrospective study of 79 patients in japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002461/
https://www.ncbi.nlm.nih.gov/pubmed/36901553
http://dx.doi.org/10.3390/ijerph20054545
work_keys_str_mv AT otsurumitsunobu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT yanamotosouichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT yamadashinichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT nakashirokohichi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT harazonoyosuke radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT kohgotomoyuki radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT nakamuramoriyoshi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT nomuratakeshi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT kasamatsuatsushi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT tanakasusumu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT kiritatadaaki radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT kioimitomu radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT ogawamasaru radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT sasakimasashi radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT otayoshihide radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan
AT umedamasahiro radiotherapypluscetuximabforsquamouscellcarcinomaoftheoralcavityamulticenterretrospectivestudyof79patientsinjapan